Ballok Zita E
Mayne Health Diagnostic Imaging Unit, Epworth Hospital, 89 Bridge Road, Richmond, Melbourne, Vic. 3121, Australia.
Heart Lung Circ. 2005;14 Suppl 2:S27-30. doi: 10.1016/j.hlc.2005.08.012. Epub 2005 Nov 4.
Nuclear cardiology has shown double digit growth yearly over the last few years and remains the second most commonly performed noninvasive cardiac imaging investigation of choice. Approximately 9 million studies performed yearly in the U.S. alone. As cardiovascular disease remains the largest healthcare problem around the world despite increasing healthcare spending there is growing interest to enhance the use of cost effective diagnostic tools, such as nuclear cardiology. Recent development of technology has seen the addition of hybrid imaging tools such PET/CT and SPECT/CT into the armorial. More data is expected to become available on this subject within the next few years, and we also expect several molecular imaging tests to become available for clinical use. Despite easy availability of these diagnostic tools, cardiac mortality and morbidity in patients with long term diabetes and also in the postoperative setting remains unexpectedly high and emergency department physician are still being sued after patients being discharged with undiagnosed chest pain. The value of the use of nuclear cardiology studies is briefly reviewed in these clinical settings.
在过去几年中,核心脏病学每年都呈现两位数的增长,并且仍然是第二常用的非侵入性心脏成像检查手段。仅在美国,每年就进行约900万次相关检查。尽管医疗保健支出不断增加,但心血管疾病仍然是全球最大的医疗问题,因此人们越来越关注提高成本效益高的诊断工具的使用,例如核心脏病学。技术的最新发展使得PET/CT和SPECT/CT等混合成像工具加入了这一领域。预计在未来几年内会有更多关于这个主题的数据,并且我们还预计会有几种分子成像测试可供临床使用。尽管这些诊断工具很容易获得,但长期糖尿病患者以及术后患者的心脏死亡率和发病率仍然出奇地高,而且在患者因未确诊的胸痛出院后,急诊科医生仍会被起诉。本文简要回顾了在这些临床环境中使用核心脏病学检查的价值。